pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ... , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 0.59 [0.46, 0.76]< 10%1 study (1/-)100.0 %NAnot evaluable important-
DCR 0.90 [0.37, 2.17]> 10%1 study (1/-)40.8 %NAnot evaluable non important-
DOR 0.45 [0.28, 0.72]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) 1.09 [0.71, 1.68]> 10%1 study (1/-)66.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.98 [0.02, 49.72]< 10%1 study (1/-)50.4 %NAnot evaluable non important-
AE (grade 3-4) 1.97 [1.34, 2.90]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to death (grade 5) 4.10 [0.18, 91.44]< 10%1 study (1/-)18.9 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 1.22 [0.68, 2.17]< 10%1 study (1/-)25.5 %NAnot evaluable non important-
SAE (any grade) 1.58 [1.02, 2.43]< 10%1 study (1/-)1.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.